Diabetic Nephropathy

Learners will review the clinical manifestations leading to the development and stage progression of diabetic nephropathy and evolving therapeutic approaches.

Original Release Date: November 2018
Review Date: October 2021

Target Audience

Hospitalists, Internists, Family Practitioners, Cardiologists, Endocrinologists, Pharmacists and other interested healthcare practitioners.

Learning Objectives

  • Describe the prevalence of diabetic nephropathy and recognize its role as a major contributor to end-stage kidney disease in the U.S.
  • Recognize the clinical manifestations leading to the development and stage progression of diabetic nephropathy.
  • Utilize evolving therapeutic approaches to the treatment of diabetic nephropathy, including new diabetes drugs, dialysis and kidney transplantation.
Additional information
Bibliography: 
  • Gallagher, H., & Suckling, R. J. (2016). Diabetic nephropathy: where are we on the journey from pathophysiology to treatment? Diabetes, Obesity and Metabolism, 18(7), 641-647.
  • Duran-Salgado, M. B., & Rubio-Guerra, A. F. (2014). Diabetic nephropathy and inflammation. World journal of diabetes, 5(3), 393.
Course Summary
Available credit: 
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 General certificate of attendance
  • 0.75 Florida Board of Pharmacy
Course opens: 
11/01/2018
Course expires: 
09/30/2022

Gaspar Alejandro Barreto-Torrella, M.D.
Nephrologist
Baptist, South Miami and West Kendall Baptist Hospitals
Miami, Florida

Gaspar Alejandro Barreto-Torrella, M.D., faculty of this educational activity, has no relevant financial relationships with ineligible companies* to disclose and has indicated that the presentation or discussion will not include off-label or unapproved product usage. 

Arturo Fridman, M.D., conference director of this educational activity, has no relevant financial relationships with ineligible companies* to disclose. 

Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose with ineligible companies*.

*Ineligible companies -- Companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Disclosure Policy and Disclaimer

Baptist Health South Florida is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Baptist Health has been re-surveyed by the ACCME and awarded Commendation for 6 years as a provider of CME for physicians.
             
Baptist Health South Florida designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


 

Available Credit

  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 General certificate of attendance
  • 0.75 Florida Board of Pharmacy
Please login or register for a Baptist Health CME account to take this course.

Required Hardware/Software

Thank you for visiting the Baptist Health CME Portal.

Your certificate will be available after course completion ONLY if the user profile fields shown below are accurate.

If any of this information is incorrect or missing, please update it using one of the links below. Inaccurate data will result in reporting errors.

Profession: [current-user:profile-profile:field-profession]
Occupation: [current-user:profile-profile:field-learner-type]
License #: [current-user:profile-profile:field-license-number]
Mobile Phone #: [current-user:sms-user-phone-number]


UPDATE PROFILE  UPDATE MOBILE NUMBER

Have you updated your email address lately? Please update your email to ensure you receive all CME communications regarding upcoming live meetings, symposiums and online course offerings. Click here to update your email preferences.

Please visit BaptistHealth.net/CME for detailed information about all upcoming CME/CE activities. 

We appreciate your participation in the Baptist Health CME Program.